Literature DB >> 20850540

Intracellular signaling and hepatocellular carcinoma.

Polina Iakova1, Lubov Timchenko, Nikolai A Timchenko.   

Abstract

Liver cancer is the fifth most common cancer and the third most common cause of cancer related death in the world. The recent development of new techniques for the investigations of global change in the gene expression, signaling pathways and wide genome binding has provided novel information for the mechanisms underlying liver cancer progression. Although these studies identified gene expression signatures in hepatocellular carcinoma, the early steps of the development of hepatocellular carcinomas (HCC) are not well understood. The development of HCC is a multistep process which includes the progressive alterations of gene expression leading to the increased proliferation and to liver cancer. This review summarizes recent progress in the identification of the key steps of the development of HCC with the focus on early events of carcinogenesis and on the role of translational and epigenetic alterations in the development of HCC. Quiescent stage of the liver is supported by several tumor suppressor proteins including p53, Rb and C/EBPα. Studies with chemical models of liver carcinogenesis and with human HCC have shown that the elevation of gankyrin is responsible for the elimination of these three proteins at early steps of carcinogenesis. Later stages of progression of the liver cancer are associated with alterations in many signaling pathways including translation which leads to epigenetic silencing/activation of many genes. Particularly, recent reports suggest a critical role of histone deacetylase 1, HDAC1, in the development of HCC through the interactions with transcription factors such as C/EBP family proteins.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20850540      PMCID: PMC3228644          DOI: 10.1016/j.semcancer.2010.09.001

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  96 in total

Review 1.  Hepatocellular carcinoma pathogenesis: from genes to environment.

Authors:  Paraskevi A Farazi; Ronald A DePinho
Journal:  Nat Rev Cancer       Date:  2006-09       Impact factor: 60.716

2.  Activation of CCAAT/enhancer-binding protein (C/EBP) alpha expression by C/EBP beta during adipogenesis requires a peroxisome proliferator-activated receptor-gamma-associated repression of HDAC1 at the C/ebp alpha gene promoter.

Authors:  Ying Zuo; Li Qiang; Stephen R Farmer
Journal:  J Biol Chem       Date:  2006-01-23       Impact factor: 5.157

Review 3.  Genetics of hepatocellular carcinoma.

Authors:  Andreas Teufel; Frank Staib; Stephan Kanzler; Arndt Weinmann; Henning Schulze-Bergkamen; Peter-R Galle
Journal:  World J Gastroenterol       Date:  2007-04-28       Impact factor: 5.742

4.  Age-specific CUGBP1-eIF2 complex increases translation of CCAAT/enhancer-binding protein beta in old liver.

Authors:  Lubov T Timchenko; Elizabeth Salisbury; Guo-Li Wang; Heather Nguyen; Jeffrey H Albrecht; John W B Hershey; Nikolai A Timchenko
Journal:  J Biol Chem       Date:  2006-08-24       Impact factor: 5.157

5.  Spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice.

Authors:  Insook Kim; Keiichirou Morimura; Yatrik Shah; Qian Yang; Jerrold M Ward; Frank J Gonzalez
Journal:  Carcinogenesis       Date:  2006-12-20       Impact factor: 4.944

6.  Cooperative interactions of p53 mutation, telomere dysfunction, and chronic liver damage in hepatocellular carcinoma progression.

Authors:  Paraskevi A Farazi; Jonathan Glickman; James Horner; Ronald A Depinho
Journal:  Cancer Res       Date:  2006-05-01       Impact factor: 12.701

7.  Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor.

Authors:  Fan Yang; Xiongfei Huang; Tangsheng Yi; Yun Yen; David D Moore; Wendong Huang
Journal:  Cancer Res       Date:  2007-02-01       Impact factor: 12.701

Review 8.  Liver diseases in the elderly: an update.

Authors:  Annarosa Floreani
Journal:  Dig Dis       Date:  2007       Impact factor: 2.404

9.  Loss of p53 and Ink4a/Arf cooperate in a cell autonomous fashion to induce metastasis of hepatocellular carcinoma cells.

Authors:  Ya-Wen Chen; David S Klimstra; Michelle E Mongeau; Jessica L Tatem; Victor Boyartchuk; Brian C Lewis
Journal:  Cancer Res       Date:  2007-08-15       Impact factor: 12.701

10.  Hepatitis B virus X protein and the estrogen receptor variant lacking exon 5 inhibit estrogen receptor signaling in hepatoma cells.

Authors:  Juqiang Han; Lihua Ding; Bin Yuan; Xiao Yang; Xiaohui Wang; Jiezhi Li; Qiujun Lu; Cuifen Huang; Qinong Ye
Journal:  Nucleic Acids Res       Date:  2006-06-06       Impact factor: 16.971

View more
  36 in total

1.  Farnesoid X receptor directly regulates xenobiotic detoxification genes in the long-lived Little mice.

Authors:  Yanjun Jiang; Jingling Jin; Polina Iakova; Julio Cesar Hernandez; Nicole Jawanmardi; Emily Sullivan; Grace L Guo; Nikolai A Timchenko; Gretchen J Darlington
Journal:  Mech Ageing Dev       Date:  2013-09-02       Impact factor: 5.432

2.  Potent effects of dioscin against hepatocellular carcinoma through regulating TP53-induced glycolysis and apoptosis regulator (TIGAR)-mediated apoptosis, autophagy, and DNA damage.

Authors:  Zhang Mao; Xu Han; Dahong Chen; Youwei Xu; Lina Xu; Lianhong Yin; Huijun Sun; Yan Qi; Lingling Fang; Kexin Liu; Jinyong Peng
Journal:  Br J Pharmacol       Date:  2019-03-18       Impact factor: 8.739

3.  RB and p53 cooperate to prevent liver tumorigenesis in response to tissue damage.

Authors:  A Kathleen McClendon; Jeffry L Dean; Adam Ertel; Zhiyan Fu; Dayana B Rivadeneira; Christopher A Reed; Ryan J Bourgo; Agnieszka Witkiewicz; Sankar Addya; Christopher N Mayhew; H Leighton Grimes; Paolo Fortina; Erik S Knudsen
Journal:  Gastroenterology       Date:  2011-06-24       Impact factor: 22.682

4.  Dysregulated hepatic bile acids collaboratively promote liver carcinogenesis.

Authors:  Guoxiang Xie; Xiaoning Wang; Fengjie Huang; Aihua Zhao; Wenlian Chen; Jingyu Yan; Yunjing Zhang; Sha Lei; Kun Ge; Xiaojiao Zheng; Jiajian Liu; Mingming Su; Ping Liu; Wei Jia
Journal:  Int J Cancer       Date:  2016-06-17       Impact factor: 7.396

5.  FXR-Gankyrin axis is involved in development of pediatric liver cancer.

Authors:  Leila Valanejad; Kyle Lewis; Mary Wright; Yanjun Jiang; Amber D'Souza; Rebekah Karns; Rachel Sheridan; Anita Gupta; Kevin Bove; David Witte; James Geller; Gregory Tiao; David L Nelson; Lubov Timchenko; Nikolai Timchenko
Journal:  Carcinogenesis       Date:  2017-07-01       Impact factor: 4.944

Review 6.  Gankyrin as a potential therapeutic target for cancer.

Authors:  Chongchong Wang; Li Cheng
Journal:  Invest New Drugs       Date:  2017-05-19       Impact factor: 3.850

7.  Retinoic acid receptor-related receptor alpha (RORalpha) is a prognostic marker for hepatocellular carcinoma.

Authors:  Rong-Dang Fu; Chun-Hui Qiu; Hu-An Chen; Zhi-Gang Zhang; Min-Qiang Lu
Journal:  Tumour Biol       Date:  2014-05-06

Review 8.  Progress in the treatment of pulmonary metastases after liver transplantation for hepatocellular carcinoma.

Authors:  Zhan-Wang Xiang; Lin Sun; Guo-Hong Li; Rakesh Maharjan; Jin-Hua Huang; Chuan-Xing Li
Journal:  World J Hepatol       Date:  2015-09-18

9.  Exogenous hydrogen sulfide promotes hepatocellular carcinoma cell growth by activating the STAT3-COX-2 signaling pathway.

Authors:  Yulan Zhen; Qiaomei Wu; Yiqian Ding; Wei Zhang; Yuansheng Zhai; Xiaoxiong Lin; Yunxia Weng; Ruixian Guo; Ying Zhang; Jianqiang Feng; Yiyan Lei; Jingfu Chen
Journal:  Oncol Lett       Date:  2018-03-02       Impact factor: 2.967

10.  Early detection of hepatocellular carcinoma co-occurring with hepatitis C virus infection: A mathematical model.

Authors:  Abdel-Rahman Nabawy Zekri; Amira Salah El-Din Youssef; Yasser Mabrouk Bakr; Reham Mohamed Gabr; Ola Sayed Ahmed; Mostafa Hamed Elberry; Ahmed Mahmoud Mayla; Mohamed Abouelhoda; Abeer A Bahnassy
Journal:  World J Gastroenterol       Date:  2016-04-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.